New TK2d Early Symptom Reflection Tool Supports Better Clinical Conversations
UMDF, in collaboration with UCB, has launched a new resource designed specifically for people living with TK2d and those who […]
The role of amino acids in some forms of mito
On May 9, 2026, International Mito Patients was represented at the Cognate Amino Acid for tRNA Synthetase Disorders Consortium meeting
UCB calls all artists in the mitochondrial disease community
This year UCB is collaborating with the global Mitochondrial disease community to collect works of art (painting, poetry, photography, sculpture,
Effect of a Mitochondrial Genetic Variant on Sevoflurane Hypersensitivity
Five years ago, a research project began that is now influencing anesthetic practice worldwide. It all started when Dr. Yaremy
First Patient Dosed in Phase 3 KHENERFIN Study of Sonlicromanol for m.3243A>G Primary Mitochondrial Disease
First Patient Dosed in Phase 3 KHENERFIN Study of Sonlicromanol for m.3243A>G Primary Mitochondrial Disease Khondrion has announced a major
IMP welcomes European Commission approval of KYGEVVI® for TK2d
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as
Announcing IMP’s New Scientific and Medical Advisory Committee
Announcing IMP’s New Scientific and Medical Advisory Committee IMP is delighted to introduce our new Scientific and Medical Advisory Committee, a
New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide
New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide In November 2025, leading international experts gathered in Pisa,
MitMED – Building a European Centre of Excellence in Mitochondrial Medicine
MitMED – Building a European Centre of Excellence in Mitochondrial Medicine Mitochondria are central regulators of cellular life, integrating metabolism,
Growing Recognition of the Patient Voice in Research
Growing Recognition of the Patient Voice in Research A meaningful shift is taking place in the rare disease research landscape: